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Background: There has been a profound decline in total mortality and cardiovascular mortality over the past 30 years. Much of this decline has 
been ascribed to changes in lifestyle and medical practice over this timeframe. There is less data on which disease states have had the greatest 
decline in mortality. This study is an attempt to determine whether this decline encompasses all major cardiovascular states.
Methods: We found all major cardiovascular clinical trials published in major medical and cardiac journals in the past 25 years and then 
calculated the age and gender adjusted mortality hazard ratio. This allows us to compare mortality between studies and over time. We then 
divided these studies into their underlying cardiovascular pathology and compared cardiovascular, noncardiovascular, and total mortality in these 
populations over time. We utilized the mortality in the control (placebo) arm in 685 study populations.
Results: There has been a stepwise and significant 70% reduction in cardiovascular mortality and a 60% reduction in overall mortality in the past 
20 years when viewed in the composite. This was seen in virtually all subgroups: chronic CAD (66%), acute MI (55%), CHF (73%), primary prevention 
(70%), hypertension (56%), and acute MI, survived 1 month (65%). Atrial fibrillation had only a 32% reduction in CV mortality. Likewise, there were 
large decreases in total mortality in most groups, with smaller percentage decreases in the hypertension (29%), CAD (47%), and primary prevention 
(50%) populations. Noncardiovascular mortality, overall and in the subgroups, did not change significantly over this same timeframe.
Conclusions: The reduction in cardiovascular mortality is universal in virtually all major subgroups of cardiovascular diseases. This is the 
sole driver of the overall decrease in mortality seen in cardiovascular clinical trials in the past 2 decades with no concomitant change in 
noncardiovascular mortality over time in these same trials. It may become increasingly difficult to sustain this trend, with a lower mortality baseline 
and fewer interventions demonstrating mortality benefit.
